Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection
A Randomized, Multicenter, Phase I/IIa Clinical Study to Evaluate the Tolerability, Safety, Efficacy, Pharmacokinetics and Immunogenicity of GB221 for Injection for the Treatment of HER2-positive Breast Cancer Patients
Sponsor: Genor Biopharma Co., Ltd.
A PHASE1/PHASE2 clinical study on HER2-positive Breast Cancer, this trial is ongoing. The trial is conducted by Genor Biopharma Co., Ltd. and has accumulated 8 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1/PHASE2
Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Apr 2023 — Jul 2024 [monthly]
Unknown Status PHASE1_PHASE2
Status: Recruiting → Unknown Status
-
Apr 2021 — Apr 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 3 earlier versions
-
Jun 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2020 — Jun 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Dec 2019 — Jan 2020 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Mar 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Genor Biopharma Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .